CDK8 regulates E2F1 transcriptional activity through S375 phosphorylation

Oncogene

Volumn 32, Issue 30, 2013, Pages 3520-3530

  Zhao, J ^a   Ramos, R ^a   Demma, M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

CDK8; E2F1; Phosphorylation; Transcriptional regulation; Tumor suppressor

Indexed keywords

BETA CATENIN; CYCLIN A; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE 8; MYC PROTEIN; PROTEIN P53; SERINE; TRANSCRIPTION FACTOR E2F1;

ARTICLE; BINDING SITE; CELL STRAIN HEK293; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; WESTERN BLOTTING; WILD TYPE;

CYCLIN-DEPENDENT KINASE 8; E2F1 TRANSCRIPTION FACTOR; HUMANS; PHOSPHORYLATION; SERINE; TRANSCRIPTIONAL ACTIVATION;

EID: 84880923558     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.364     Document Type: Article

References (42)

1. Walther A, Kohnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489-499.
2. Firestein R, Hahn WC. Revving the throttle on an oncogene: CDK8 takes the driver seat. Cancer Res 2009; 69: 7899-7901.
3. Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E et al. CDK8 expression in 470 colorectal cancers in relation to b-catenin activation, other molecular alterations, and patient survival. Int J Cancer 2009; 126: 2863-2873.
4. Moon RT, Kohn AD, DeFerrari GV, Kykas A. Wnt and b-catenin signaling and therapies. Nat Rev Genet 2004; 5: 689-699.
5. Clevers H. Wnt/β-catenin signaling in development and disease. Cell 2006; 127: 469-480.
6. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006; 281: 22429-22433.
7. Verma U, Surrabbi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against β-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003; 9: 1291-1300. (Pubitemid 36418379)
8. Agarwal A, Das K, Lerner N, Sathe S, Ciecek M, Casey G et al. AKT/IκB kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-κB and β-catenin. Oncogene 2005; 24: 1021-1031. (Pubitemid 40313879)
9. Kim S, Xu X, Hecht A, Boyer TG. Mediator is a transducer of Wnt/β-catenin signaling. J Biol Chem 2006; 281: 14066-14075.
10. Taatjes D. The human mediator complex: a versatile, genome-wide regulator of transcription. Trends Biochem Sci 2010; 35: 315-322.
11. Woychick NA, Hampsey M. The RNA polymerase II machinery: structure illuminates function. Cell 2002; 108: 453-463. (Pubitemid 34260871)
12. Galbraith MD, Donner AJ, Espinosa JM. CDK8 a positive regulator of transcription. Transcription 2010; 1: 4-12.
13. Xu W, Ji J-Y. Dysregulation of CDK8 and Cyclin C in tumorgenesis. J Genet Genomics 2011; 38: 439-452.
14. Firestein R, Bass AJ, Kim SY, Dunn IF, Silver SJ, Guney I et al. CDK8 is a colorectal cancer oncogene that regulates β-catenin activity. Nature 2008; 455: 547-551.
15. Kapoor A, Goldberg MS, Cumberland LK, Ratnakumar K, Segura MF, Emanuel PO et al. The histone variant macroH2A suppresses melanoma progression through regulation of CDK8. Nature 2010; 468: 1105-1109.
16. Meyer KD, Donner AJ, Knuessel MT, York AG, Espinosa JM, Taatjes DJ. Cooperative activity of CDK8 and GCNL5 within mediator directs tandem phosphoacetylation of histone H3. EMBO J 2008; 27: 1447-1457. (Pubitemid 351733333)
17. Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ. The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol 2009; 29: 650-661.
18. Donner AJ, Szostek S, Hoover JM, Espinosa JM. CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell 2007; 27: 121-133. (Pubitemid 46991381)
19. Donner AJ, Ebmeier CC, Taatjes DJ, Espinosa JM. CDK8 is a positive regulator of transcriptional elongation within the serum response network. Nat Struct Mol Biol 2010; 17: 194-202.
20. Rickert P, Corden JL, Lees E. CyclinC/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases. Oncogene 1999; 18: 1093-1102. (Pubitemid 29086287)
21. Fryer CJ, White B, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell 2004; 16: 509-520. (Pubitemid 39531875)
22. Alacron C, Zaromytidou A-I, Xi Q, Gao S, Yu J, Fujisawa S et al. Nuclear CDKs drive smad transcriptional activation and turnover in BMP and TGF-β pathways. Cell 2009; 139: 757-769.
23. Gao S, Alacon C, Sapkota G, Rahman S, Chen P-Y, Goerner N et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-β signaling. Mol Cell 2009; 36: 457-468.
24. Morris EJ, Ji J-Y, Yang F, DiStefano L, Herr A, Moon NS et al. E2F1 represses β-catenin transcription and is antagonized by pRB and CDK8. Nature 2008; 455: 552-556.
25. Bieda M, Xu X, Singer MA, Green R, Farnham PJ. Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. Genome Res 2006; 16: 595-605.
26. Ji J-Y, Dyson NJ. Interplay between cyclin-dependent kinases and E2F-dependent transcription. In: Enders GH (ed.) Cell Cycle Deregulation in Cancer. Springer Science, New York, NY, 2010, pp 23-41.
27. Tago K, Nakamura T, Nishita M, Hyodo J, Nagai S, Murata Y et al. Inhibition of Wnt signaling by ICAT, a novel β-catenin-interacting protein. Genes Dev 2000; 14: 1741-1749. (Pubitemid 30602993)
28. Graham T, Clemente WK, Kimelman D, Wu W. The crystal structure of β-catenin/ICAT complex reveals the inhibitory mechanism of ICAT. Mol Cell 2002; 10: 563-571. (Pubitemid 35284174)
29. Wu Z, Zheng S, Li Z, Tan J, Yu Q. E2F1 suppresses Wnt/β-catenin activity through transactivation of b-catenin interacting protein ICAT. Oncogene 2011; 30: 3979-3984.
30. Helin K. Regulation of cell proliferation by E2F transcription factors. Curr Opin Genet Dev 1998; 8: 28-35. (Pubitemid 28122137)
31. Mundle SD, Saberwal G. Evolving intricacies and implications of E2F1 regulation. Faseb J 2003; 17: 569-574. (Pubitemid 37221141)
32. Krek W, Ewen ME, Shirodkar S, Arany Z, Kaelin Jr WG, Livingstone DM. Negative regulation of the growth-promoting transcription factor E2F1 by a stably bound cyclin 1-dependent protein kinase. Cell 1994; 78: 161-172. (Pubitemid 24228310)
33. Xu M, Sheppard K-A, Peng C-Y, Yee AS, Piwnica-Worms H. Cyclin A/CDK2 binds directly to E2F1 and inhibits the DNA-binding activity of E2F1/DP-1 by phosphorylation. Mol Cell Biol 1994; 14: 8420-8431. (Pubitemid 24373591)
34. Peeper DS, Keblusek P, Helin K, Toebes M, van der Eb AJ, Zantema A. Phosphorylation of a specific CDK site in E2f1 affects its electrophoretic mobility and promotes pRB-binding in vitro. Oncogene 1995; 10: 39-48.
35. Vandel L, Kouzarides T. Residues phosphorylated by TFIIH are required for E2F-1 degradation during S-phase. EMBO J 1999; 18: 4280-4291. (Pubitemid 29364130)
36. Ohantani K, Nevins JR. Functional properties of a Drosophilia Homolog of the E2F1 gene. Mol Cell Biol 1994; 14: 1603-1612. (Pubitemid 24074556)
37. Nair JS, Ho AL, Tse AN, Coward J, Cheema H, Ambrosini G et al. Aurora B kinase regulates postmitotic endoduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780. Mol Biol Cell 2009; 20: 2218-2228.
38. Hurford Jr RK, Cobrinik D, Lee MY, Dyson N. pRb and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. Genes Dev 1997; 11: 1447-1463. (Pubitemid 27259855)
39. Bandara LR, Buck VM, Zamanian M, Johnson LH, LaThangue NB. Functional synergy between DP-1 and E2F1in the cell cycle regulating transcription factor E2F/DRTF. EMBO J 1993; 12: 4317-4324. (Pubitemid 23302046)
40. Zhang J, Li H, Yabut O, Fitzpatrick H, D'Arcangelo G, Herrup K. CDK5 suppresses the neuronal cell cycle by disrupting the E2F1-DP1 complex. J Neurosci 2010; 30: 5219-5228.
41. Knuesel MT, Meyer KD, Bernecky C, Taatjes DJ. The human CDK8 subcomplex is a molecular switch that controls mediator coactivator function. Genes Dev 2009; 23: 439-451.
42. DePhoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP. A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci USA 2008; 105: 10762-10767.